ArticleCancer medicine2018
Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes.
Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Comparative survival outcomes between therapy-related and de novo acute lymphoblastic leukemia in adults: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Survival outcomes in secondary and primary acute lymphoblastic leukemia: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.Leukemia research · 2018Pooled it
- Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared toHaematologica · 2018Trial
- Review
- Co-occurrence of thymoma and acute T-lymphoblastic leukemia/lymphoma: a case report and literature review.Mediastinum (Hong Kong, China) · 2025Article
- Characteristics and outcomes of secondary acute lymphoblastic leukemia (sALL) after multiple myeloma (MM): SEER data analysis in a single-center institution.Cancer pathogenesis and therapy · 2025Article
- Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registry.Bone marrow transplantation · 2024Article
- The feasibility of PETHEMA ALL-96 regimen on treatment of patients with acute lymphoid leukemia.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Article
- Primary blastic plasmacytoid dendritic cell neoplasm: a US population-based study.Frontiers in oncology · 2023Article
- Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma.Blood cancer journal · 2022Article
- Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.British journal of haematology · 2022Article
- Therapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared toJournal of Cancer · 2022Article
- The impact of a prior malignancy on outcomes in gastric cancer patients.Cancer medicine · 2021Article
- Allogeneic hematopoietic stem cell transplantation overcomes the poor prognosis in MLL-rearranged solid tumor therapy related-acute myeloid leukemia.American journal of cancer research · 2021Article
- Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.Bone marrow transplantation · 2020Article
- Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.Blood advances · 2019Article
- Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia.Blood cancer journal · 2019Article
- Common B-cell acute lymphoblastic leukaemia in a 70-year-old woman presenting 2 years after carboplatin-taxane radiotherapy for endometrial cancer.Ecancermedicalscience · 2019Article
- Therapy-related acute lymphoblastic leukemia.Haematologica · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a surveillance epidemiology and end results (SEER)-based analysis to describe the incidence and characteristics of second primary acute lymphoblastic leukemia (sALL) among adults (≥18 years) with a history of primary malignancies (1M). Standardized incidence ratios (SIRs) of sALL cases were calculated by site and 1M stage. We also evaluated the differences in 5-year sALL survival by age, site, and extent of 1M, latency of sALL after 1M, and evidence of underlying racial/ethnic disparity. We identified 10,956 patients with de-novo/primary acute lymphoblastic leukemia (1ALL) and 772 with sALL. Women (49.1% vs. 42.9%), white patients (72.0% vs. 59.5%), older patients (58.8% vs. 25.2%; age ≥65 years), and patients diagnosed between 2003 and 2012 (66.8% vs. 53.9%) had a higher proportion of sALL compared with 1ALL. There was a significantly inferior median 5-year survival for sALL patients compared to 1ALL (6 vs. 15 months; HR 1.20, 95% CI 1.10-1.31, P < 0.001). The median latency period was 60.0 months; the most common 1M among sALL patients were breast (17.9%) and prostate (17.4%). Patients with any 1M were at increased risk of developing sALL (SIR 1.76, 95% CI 1.58-1.95, P < 0.001). Hematological-1M sites had significantly higher SIRs (hematological-SIR 7.35; solid-SIR 1.33; P < 0.001). We observed a significant increase in sALL incidence after a 1M and a significantly worse 5-year survival with different demographic characteristics from 1ALL. There is a need to define appropriate screening methods for patients surviving their primary cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.